Various studies suggest that ARL4C plays a crucial role in intensifying tumor proliferation, invasion, and drug resistance via immune-related pathways, which include Wnt/β-catenin, AKT/mTOR, and MEK/ERK (42–44). Here, AKT1 is linked to neoplasm.